NCT01218230View on ClinicalTrials.gov

Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Myopic Choroidal Neovascular Membrane
Interventions
DRUG

Intravitreal Pegaptanib

Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.

Trial Locations (1)

500034

LV Prasad Eye Institute, Hyderabad

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

L.V. Prasad Eye Institute

OTHER